Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 226 to 250 of 2524

TitleReference numberPublishedLast updated
Phrenic nerve pacing for congenital central hypoventilation syndromeIPG790
Caval valve implantation for tricuspid regurgitationIPG791
Relugolix for treating hormone-sensitive prostate cancerTA995
Linzagolix for treating moderate to severe symptoms of uterine fibroidsTA996
Diabetic retinopathy: management and monitoringNG242
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Abaloparatide for treating osteoporosis after menopauseTA991
Burosumab for treating X-linked hypophosphataemia in adultsTA993
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackHTG724
AnaphylaxisQS119
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTA988
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia BTA989
Tenecteplase for treating acute ischaemic strokeTA990
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)TA987
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgusIPG789
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977

Results per page

  1. 10
  2. 25
  3. 50
  4. All